SCA
OCUL icon

Spearhead Capital Advisors’s Ocular Therapeutix OCUL Stock Holding History

Spearhead Capital Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-24,303
Closed -$169K – 219
2021
Q4 		$169K Buy
24,303
+373
+2% +$2.9K 0.02% 172
2021
Q3 		$239K Sell
23,930
-204
-0.8% -$2.29K 0.03% 177
2021
Q2 		$342K Buy
24,134
+3,853
+19% +$58.6K 0.05% 166
2021
Q1 		$333K Buy
+20,281
New +$391K 0.05% 138

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Spearhead Capital Advisors's OCUL Position: Q1 2022 in Review

Spearhead Capital Advisors sold out of Ocular Therapeutix (OCUL) in Q1 2022, closing a stake of 24,303 shares — an estimated $169K sold.

Spearhead Capital Advisors first reported a position in OCUL in Q1 2021 and held it in 4 quarters. The position peaked at $342K in Q2 2021. 132 funds tracked by Wall St. Rank hold OCUL as of Q1 2022.

  • Spearhead Capital Advisors reported no remaining Ocular Therapeutix position as of Q1 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 24,303 Ocular Therapeutix shares in Q1 2022, an estimated $169K.
  • Spearhead Capital Advisors first reported a position in Ocular Therapeutix in Q1 2021 and held it in 4 quarters.
  • Spearhead Capital Advisors's Ocular Therapeutix position peaked at $342K in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2022.

Based on Spearhead Capital Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.